MG
DGX icon

Mather Group’s Quest Diagnostics DGX Stock Holding History

Mather Group’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$291K Sell
1,374
-28
-2% -$5.5K ﹤0.01% 681
2026
Q1 		$275K Buy
1,402
+221
+19% +$42.9K ﹤0.01% 647
2025
Q4 		$205K Sell
1,181
-711
-38% -$129K ﹤0.01% 623
2025
Q3 		$361K Buy
1,892
+435
+30% +$77.2K ﹤0.01% 465
2025
Q2 		$262K Buy
1,457
+367
+34% +$63.7K ﹤0.01% 532
2025
Q1 		$184K Buy
1,090
+326
+43% +$53.6K ﹤0.01% 615
2024
Q4 		$115K Buy
764
+72
+10% +$11.2K ﹤0.01% 707
2024
Q3 		$107K Sell
692
-17
-2% -$2.54K ﹤0.01% 719
2024
Q2 		$94.2K Buy
709
+276
+64% +$37.8K ﹤0.01% 824
2024
Q1 		$59.6K Buy
+433
New +$56.2K ﹤0.01% 832

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Mather Group's DGX Position: Q2 2026 in Review

Mather Group reduced its Quest Diagnostics (DGX) stake by 2% in Q2 2026, selling an estimated $5.5K and leaving 1,374 shares worth $291K. The position accounts for ﹤0.01% of the portfolio, ranked #681.

Mather Group first reported a position in DGX in Q1 2024 and has held it in 10 quarters since. The position peaked at $361K in Q3 2025. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Mather Group held 1,374 shares of Quest Diagnostics worth $291K as of Q2 2026.
  • Mather Group sold 28 Quest Diagnostics shares in Q2 2026, an estimated $5.5K.
  • Quest Diagnostics made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #681 holding.
  • Mather Group first reported a position in Quest Diagnostics in Q1 2024 and has held it in 10 quarters since.
  • Mather Group's Quest Diagnostics position peaked at $361K in Q3 2025.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.